Universal Detection Presents Bio-Threat Monitoring Technology

LOS ANGELES--(BUSINESS WIRE)--Dec. 1, 2005--Universal Detection Technology (OTCBB:UDTT) (FWB:PO8), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, will present its advanced bio-threat monitoring technology to industry and scientific leaders at Biosensing Technologies for Medical and Homeland Security Applications, an international conference organized by a leading United Kingdom-based university and business development alliance and to be held at the California Institute of Technology.

UDTT's Director of Research and Development, Amir Ettehadieh, will discuss the Company's bacterial spore detection technology. UDTT develops and distributes advanced early-warning monitoring and detection systems with cost and functional advantages over competing technologies available. UDTT's product, the BSM-2000, is designed to monitor and detect the presence of anthrax, a highly lethal biological agent that is considered one of the most serious bioterrorism threats. The Company has exclusive commercial rights to bacterial spore detection technology developed by NASA's JPL.

The conference is coordinated by the Institute of Bioscience and Technology, at Cranfield University, in the UK. The institution is Western Europe's largest organization for applied research, strategic development and management. The mission of this year's Biosensing Technologies for Medical and Homeland Security Applications gathering, being held in Pasadena, California, at the California Institute of Technology Nov. 28 through Dec. 2, is to examine the current status of leading edge biosensor and biosensing technologies in the medical and biodefense sectors in the USA. Presenters will explore a range of advanced biosensing technologies.

"Universal Detection is pleased to participate in the Biosensing conference and to discuss our technology," said Jacques Tizabi, CEO of UDTT. "This forum is expected to be an excellent opportunity for our Company representatives to meet with a range of executives and to establish new commercial relationships."

Biosensors and biosensing are major global industries, with worldwide annual sales of medical biosensors exceeding $6.4 billion in 2003, according to conference organizers. In addition, security-oriented organizations in nations around the world are allocating significant new levels of resources to bolster public safety and preparedness against bioterrorism and related threats, said Mr. Tizabi. "With our technology, UDTT is providing solutions to create highly sensitive, integrated, cost-effective and reliable monitoring and early warning systems to safeguard lives in the event of bioterrorism attacks," he said.

About Universal Detection Technology

Universal Detection Technology (UDTT), founded in 1973, is a developer of advanced monitoring and early-warning technologies whose mission is to help meet today's heightened security and defense requirements in the global war on terror. The Company's intellectual property portfolio includes exclusive worldwide commercial licensing of technology developed by NASA's Jet Propulsion Laboratory (JPL) and its own proprietary aerosol capture technology, which are combined in the Company's initial monitoring device, the BSM-2000. Management believes that the Company's technology, together with third-party technologies and devices, has positioned it to capitalize on growth and value opportunities related to Homeland Security. For more information, please visit http://udtt.invrel.net or http://www.udetection.com. To view investor-specific information about the Company, including recent news and other data, please visit http://www.trilogy-capital.com/tcp/udt. To read or download an Investor Fact Sheet about the Company, please visit http://www.trilogy-capital.com/tcp/udt/factsheet.html. Universal Detection Technologies is also listed on the Frankfurt Stock Exchange under the ticker symbol PO8.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may vary substantially as a result of a variety of factors. Among the important factors that could cause actual results to differ are, the funding of amounts of capital adequate to provide for our working capital needs and our timely repayment of debt, the results of the validation testing of the BSM-2000 undertaken by an independent third party, our ability to timely and cost effectively complete the development and testing of our products targeted to the bio-chemical market, our ability to commercially produce our products and do so on a profitable basis, commercial acceptance of our products, product price volatility, product demand, market competition and general economic conditions. These and other risk factors are discussed in our periodic reports filed with the SEC, including our Report on Form 10-K for the year ended December 31, 2004 and our periodic Reports on Form 10-Q for the quarters ended March 31, 2005, June 30, 2005, and September 30, 2005 and the reader is directed to these statements for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements.

CONTACT: Universal Detection Technology Jacques Tizabi, 310-248-3655 jtizabi@udetection.com or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul@trilogy-capital.com KEYWORD: CALIFORNIA UNITED KINGDOM INTERNATIONAL EUROPEINDUSTRY KEYWORD: HARDWARE MEDICAL AEROSPACE/DEFENSE GOVERNMENT BIOTECHNOLOGY TRADESHOW PRODUCTSOURCE: Universal Detection Technology

<<Business Wire -- 12/02/05>>